Skip to main content
Caplight Logo









Beijing Inflama Lab

Beijing Inflama Lab

Private
BeijingHealthcare & Life Scienceshttps://inflamab.com

Last Round

Series B

Jul 3, 2026

Total Funding Raised

$97.22M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Beijing Inflama Lab is a biotechnology company that develops revolutionary innovative drugs for the treatment of inflammation and tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intracellular antibodyNLRP3 inhibitorantibody delivery platformantibody therapeuticsbispecific antibodyinflammatory disease therapycell-penetrating antibodiesintrabodyNLRP3 inflammasomebiologicsbiopharmadrug discoverypreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Beijing Inflama Lab Comparables

Compare Beijing Inflama Lab with similar companies based on industry and business-model similarity.

Beijing Inflama Lab comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
XtalPi
78%
DotBio
77%
Olatec Therapeutics
73%

Beijing Inflama Lab Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 3, 2026
Series A ExtensionMay 24, 2024
Series AJul 10, 2023
AngelJan 1, 2021

Beijing Inflama Lab Investors

Notable investors and investment history

Beijing Inflama Lab investors
InvestorRounds
BioTrack CapitalAngel, Series A
Beijing Chang DevelopmentSeries B, Angel, Series A
MSA CapitalSeries A, Angel
China Reform Holdings Corporation Ltd.Series B
China Reform Fund Management Co.,LtdSeries B
上海国投先导私募基金管理有限公司Series B
Frees FundSeries B, Series A Extension, Angel, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2026

    Led by 上海国投先导私募基金管理有限公司 with participation from China Reform Fund Management Co.,Ltd.

Beijing Inflama Lab Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Beijing Inflama Lab Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Beijing Inflama Lab's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Year Founded2020
Last FundingJul 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?